Dr. Michael Lidsky, MD
Claim this profileDuke University Medical Center
Studies Gallbladder Cancer
Studies Bile Duct Cancer
2 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Michael Lidsky, MD is currently running
Pre- and Post-Surgery Chemotherapy
for Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Recruiting1 award Phase 2 & 315 criteria
Chemotherapy +/− FUDR/Dexamethasone Pump
for Bile Duct Cancer
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. For the study treatment to be considered better than the standard treatment, the study treatment should increase the time until progression of disease by an average of 3 months, compared with the usual approach.
Recruiting1 award Phase 213 criteria
More about Michael Lidsky, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Lidsky, MD has experience with
- Cisplatin
- Gemcitabine Hydrochloride
- Lymphadenectomy
- Partial Hepatectomy
- Dexamethasone
- Floxuridine
Breakdown of trials Michael Lidsky, MD has run
Gallbladder Cancer
Bile Duct Cancer
Intrahepatic Cholangiocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Lidsky, MD specialize in?
Michael Lidsky, MD focuses on Gallbladder Cancer and Bile Duct Cancer. In particular, much of their work with Gallbladder Cancer has involved treating patients, or patients who are undergoing treatment.
Is Michael Lidsky, MD currently recruiting for clinical trials?
Yes, Michael Lidsky, MD is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Michael Lidsky, MD has studied deeply?
Yes, Michael Lidsky, MD has studied treatments such as Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy.
What is the best way to schedule an appointment with Michael Lidsky, MD?
Apply for one of the trials that Michael Lidsky, MD is conducting.
What is the office address of Michael Lidsky, MD?
The office of Michael Lidsky, MD is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.